Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/S0140-6736(08)61102-2 | DOI Listing |
Epidemiol Serv Saude
January 2025
Ministério da Saúde, Secretaria de Vigilância em Saúde e Ambiente, Brasília, DF, Brasil.
Objectives: To analyze access to pre-exposure prophylaxis (PrEP) for HIV in Brazil, comparing transgender and cisgender populations.
Methods: This was a descriptive study using data from the Medication Logistics Control System (Sistema de Controle Logístico de Medicamentos - SICLOM), related to the monitoring of PrEP between January 2018 and December 2023.
Results: During the period analyzed, 149,022 people initiated PrEP, of whom 139,423 (94%) were cisgender and 9,599 (6%) were transgender.
Aging Cell
January 2025
Department of Internal Medicine and Radboud Center of Infectious Diseases, Radboudumc, Radboud University, Nijmegen, The Netherlands.
Due to the increased burden of non-AIDS-related comorbidities in people living with HIV (PLHIV), identifying biomarkers and mechanisms underlying premature aging and the risk of developing age-related comorbidities is a priority. Evidence suggests that the plasma proteome is an accurate source for measuring biological age and predicting age-related clinical outcomes. To investigate whether PLHIV on antiretroviral therapy (ART) exhibit a premature aging phenotype, we profiled the plasma proteome of two independent cohorts of virally suppressed PLHIV (200HIV and 2000HIV) and one cohort of people without HIV (200FG) using O-link technology.
View Article and Find Full Text PDFGlob Health Sci Pract
January 2025
Anova Health Institute, Johannesburg, South Africa.
Background: Despite increased antiretroviral therapy (ART) access in South Africa, HIV testing and ART initiation are suboptimal in hospital settings. Key gaps include in-hospital case finding, ART initiation support, and primary health care (PHC) facility linkage after discharge.
Intervention Development And Description: We identified weaknesses in hospital processes by comparing them with PHC HIV services and developed a quality improvement model for implementation in 5 Johannesburg hospitals.
BMJ Glob Health
January 2025
CERPOP, Toulouse, France.
Introduction: We describe the 24-month incidence of Dolutegravir (DTG)-containing antiretroviral treatment (ART) initiation since its introduction in 2019 in West Africa.
Methods: We included all patients aged 0-24 years on ART from nine clinics in Côte d'Ivoire (n=4), Ghana, Nigeria, Mali, Benin, and Burkina Faso. Baseline varied by clinic and was defined as date of first DTG prescription; patients were followed up until database closure/death/loss to follow-up (LTFU, no visit ≥7 months), whichever came first.
J Int Assoc Provid AIDS Care
January 2025
Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Long-acting antiretroviral treatment (LA ART) is a forthcoming option for adolescents and young people living with HIV (AYPLHIV), but perspectives on using peer mentors to implement LA ART for AYPLHIV are unknown. We conducted seven focus group discussions ( = 58 participants) from November 2021 to April 2022 in Kenya with four stakeholder groups, including AYPLHIV, healthcare providers, advocates, and policymakers. We used inductive coding and thematic analysis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!